Ultragenyx Stock Booms After Burosumab Continues to Impress in Phase III Study

  • Post author:
  • Post category:BioPharma

Shares of Ultragenyx are sharply climbing this morning after the company announced positive results from its Phase III study of burosumab in adults with XLH.
Source: BioSpace